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Abstract  
Introduction: Secondary tumours or metastases account for more than half of all brain tumours in adults. 
Central nervous system is most commonly a target of metastatic dissemination. The judicious use of  
selected immunostains is unquestionably helpful in diagnostically challenging cases. CAM 5.2 being highly 
specific, is emerging as a specific marker to diagnose metastatic carcinoma. 
Presentation of case: Total six metastatic tumours were studied using CAM5.2. Histopathological sections 
of brain tissue were stained by routine hematoxylin and eosin (H&E) as per standard technique. 
Representative sections were subjected to immunohistochemical staining with CAM 5.2. Skin biopsy act as 
a positive control for cytokeratin.  
All of the 6 cases showed positivity for CAM 5.2. CAM5.2 expression in metastatic tumours was 
statistically significant (sensitivity 100% & 100% specificity).
Conclusion: We conclude in our study that CAM5.2 was significantly associated with metastatic tumours, 
as they were positive using this specific marker. 
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Introduction 
Central nervous system (CNS) tumours are the 
neoplasms constituting 1-2% of all the 
neoplasms [1]. Secondary tumours or metastasis 
account for more than half of all brain tumours in 
adults. Ten to 50% of patients with systemic 
malignancy develop brain metastasis during their 
disease [2]. Most common route of spread is 
through blood stream. Central nervous system is 
most commonly a target of metastatic 
dissemination from lung carcinoma (18-60%), 
breast carcinoma (5-21%), melanoma (4-16%), 
genitourinary (3-10%) and gastrointestinal 
malignancies (5-12%). Most of the metastasis is 
located in the brain hemispheres (80%), 
especially in the parietal lobe, followed by 
frontal and occipital lobes 
[3].Immunohistochemistry (IHC) has become an 
important tool in the diagnosis of brain tumours. 
Although conventional hematoxylin-eosin 
staining is the mainstay for pathologic diagnosis, 
IHC has played a major role in differential 
diagnosis. 
  GFAP is the most frequently used marker in 
diagnostic neuro-oncology [4]. Cytokeratins 
monoclonal antibodies are useful in identification 
of the epithelial nature of neoplasm. CAM 5.2 is 
the mouse monoclonal antibody raised against 
colon carcinoma cell line HT29. It stains normal 
epithelial cell with the exception of stratified 
squamous epithelium [5]. 
  Various studies have been conducted on 
metastatic brain tumours using non specific 
cytokeratins. Role of CAM 5.2 being highly 
specific is emerging as a specific marker to 
diagnose metastatic carcinoma. IHC using 
monoclonal or polyclonal antibodies has greatly 
influenced the diagnosis of various neurological 
disorders. Using this technique the presence of 
characteristic antigen can be precisely defined in 
a sensitive and reproducible manner, thereby 
providing a better tool for making an accurate 
diagnosis of brain tumours [6]. 
Materials and Methods 
After gross examination of the specimen and 
proper sampling, the tissues were processed by 
routine histological technique for paraffin 
embedding and sectioning at 4 micron thickness. 
Histopathological sections were stained by 
routine hematoxylin and eosin (H&E) as per 
standard technique. Special stain was employed 
wherever needed. Representative sections were 
subjected to immunohistochemical staining with 
CAM 5.2. Skin biopsy act as a positive control 
for cytokeratin. Negative control staining was 
obtained by substituting the primary antibody 
with an antibody of unrelated specificity. GFAP 
staining was also used to detect primary tumours 
of CNS. 
Observations 
Six cases were diagnosed as metastasis to CNS. 
Out of these, 4 cases were of metastasis from 
adenocarcinoma (Fig. 1), one case was from 
Follicular carcinoma thyroid (Fig. 2) and renal 
cell carcinoma each(Fig. 3). Three cases were 
observed in age group 51-60 years. Average age 
for metastatic tumour was 55 years. Male to 
female ratio for metastatic tumours was 2:1. The 
most favoured site for metastasis (3 cases) was 
temporal lobe. Only one case was seen in 
cerebellum. Out of six cases of metastasis, five 
cases were enhancing and one case was 
hypodense radiologically. It seems that 
enhancement is a feature of metastatic tumours. 
All of the 6 cases showed positivity for CAM 
5.2(Fig. 4 & 5). CAM5.2 expression in 
metastatic tumours was statistically significant 
(sensitivity 100% & 100% specificity) as shown 
in table below. 
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Figure 1 photomicrograph showing papillary adenocarcinoma invading glial tissue H&E(x200) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 photomicrograph showing metastatic follicular carcinoma thyroid in CNS.  H&E(x100) 
 
 
 
Ivy Union Publishing | http: //www.ivyunion.org February 14, 2014 | Volume 2 | Issue 1  
Mathur SK et al. American Journal of Medical Case Reports 2014, 2:1-8 Page 4 of 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 photomicrograph showing metastatic renal carcinoma – clear cell variant H&E(x200) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 photomicrograph showing CAM5.2 positivity in metastatic papillary adenocarcinoma IHC (CAM5.2; 
x100) 
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Figure 5 photomicrograph showing CAM5.2 positivity in metastatic renal carcinoma – clear cell variant 
IHC (CAM5.2; x100) 
 
 
                                                                   
 Table 1 Comparison of Staining of GFAP & CAM5.2 in Metastatic tumours 
 
Metastatic tumours Total number of cases CAM 5.2 (+) GFAP staining(+) 
Renal cell carcinoma 1  1 0 
Follicular carcinoma thyroid 1  1 0 
Adenocarcinoma 4  4 0 
Total no. of cases 6 6 0 
 
 
Discussion 
Although conventional H & E staining is 
mainstay for pathological diagnosis, IHC has 
played a major role in differential diagnosis and 
in improving the diagnostic accuracy in 
neurooncologic pathology. The judicious use of a 
panel of IHC is unquestionably helpful in 
diagnostically challenging cases. In fact, IHC is 
also of great help to grade and to predict the 
prognosis in certain brain tumours also. An 
understanding of the pathology of CNS tumours 
plays a vital role in the management of patients 
and in clinical and biological research. There are 
now a number of techniques that are used to 
detect the location and physiological properties 
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of intracranial tumours. They include CT, MRI, 
PET (Positron emission tomography) and the use 
of cerebral angiography for localization of 
tumours. Apart from the angiographic 
demonstration of lesions of vascular tissue, none 
of the other technique allows a specific diagnosis 
to be made with absolute certainity and biopsy is 
still the gold standard in establishing the 
diagnosis in the majority of intracranial and 
intraspinal tumours [7]. Although CT and MRI  
allow accurate localization of intracranial and 
spinal lesions, and often serve as a very good 
guide to the nature of the lesion, the final 
diagnosis of a tumour relies almost exclusively 
on histological evaluation of tissue taken at 
biopsy or autopsy. Pathology, radiology and 
clinical evaluation all play key role in the 
diagnosis of metastatic tumours of the nervous 
system. An accurate diagnosis of metastatic 
tumours is usually possible after careful 
assessment of routine microscopic features with 
sufficient clinical and radiological information  
A combination of immunostains as studied by 
Prayson et al., included GFAP and cytokeratin 
CAM5.2 in 23 patients of glioblastoma 
multiforme and 22 patients with metastatic 
carcinomas to the brain. Primary tumours were 
lung, breast and endometrium. Glioblastoma 
multiforme is characterized by the features often 
encountered in poorly differentiated metastatic 
carcinomas. The information regarding pattern of 
cytokeratin expression in GBM is little in 
literature. Only one GBM stained for CAM5.2. 
Three cases of metastatic carcinomas stained for 
GFAP. The staining in these cases was focal and 
limited to less than 10% of malignant cells. They 
concluded that CAM5.2[deleted 2 words] is 
most useful stain in studying carcinomas.[delete 
one sentence] .The combination of GFAP with 
CAM5.2 is most useful in sorting out difference 
among glial [deleted 1 word] and metastatic 
tumours.[delete one sentence]  [8]. In the study 
of  Biernat et al. Ck profile was indispensible in 
determining the site of primary tumour. He also 
found that metastasis to the brain from lung 
carcinoma also expressed CAM 5.2 [3].  Pavlidis 
et al. studied that metastatic carcinomas of 
central nervous system from an unknown 
primary, is diagnosed with either a solitary lesion 
or with multiple metastasis. Upto 15% of all 
patients with CNS metastasis had no clearly 
identified primary site despite an intensive 
investigation. Histopathologically, intracranial 
lesions are most frequently metastatic 
adenocarcinomas or metastatic squamous cell 
carcinomas. Patients with solitary lesion are 
candidate for surgery and have better prognosis. 
The development of monoclonal antibodies 
against various cytokeratins have opened up new 
avenues in investigating the normal and 
cancerous epithelial cells [9]. Perry et al. studied the 
diagnosis of metastatic adenocarcinomas to the 
brain of unknown primary. Sixty eight cases of 
metastatic adenocarcinomas to the brain with 
known primaries were immunostained with 
antibodies to cytokeratin 7 (CK 7), cytokeratin 
(CK 20) and CAM 5.2. None of the keratin 
antibody stained reactive astrocytes or other 
normal CNS parenchymal elements in any of the 
cases. Breast carcinoma and renal cell carcinoma 
also expressed CAM5.2. It is a useful 
confirmatory stain in suspected metastatic 
adenocarcinoma to the brain. Unlike non specific 
AE1/3, CAM5.2 does not stain astrocytes. AE1/3 
antibody should be avoided in the brain because 
of the common staining of both normal and 
neoplastic astrocytes, but CAM 5.2 does not 
suffer this drawback and it is expressed in 
metastatic tumours to the brain [10]. Murakata et 
al. did a study on immunohistochemical 
expression of metastatic renal tumours (clear cell 
variant) and found them to be positive for 
cytokeratin (7, 18 and 19) [11]. Expression of 
CAM5.2 was observed by Listrom et al. in 
poorly differentiated tumours and it was 
concluded that areas of necrosis and hemorrhage 
to be avoided because these areas tend to trap 
antibody which increased the background 
staining and made interpretation difficult [5]. 
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Table 2 Correlation of GFAP and CAM5.2 staining in Metastatic tumours in various studies 
 
Study Year Total cases of  
metastasis 
GFAP % of GFAP  
positivity 
CAM 5.2 % of CAM 5.2 
positivity 
   + _  + _  
Listrom  et al.[5] 1987 65 - - - 40 25 61.5% 
Prayson et al.[8] 1999 22 3 19 13.6% 22 - 100% 
Goswami et al. [12] 2004 10 - 10 0% 10 - 100% 
Present study 2012 6 - 6 0% 6 - 100% 
                                                      
Conclusion 
 To conclude in our study, CAM5.2 was 
significantly associated with metastatic tumours. 
However, the expression may vary with IHC due 
to various parameters including case selection, 
sample size & hence need to be standardized by 
more studies using the same IHC technique and a 
bigger sample size for better results. High grade 
gliomas like GBM are fairly encountered in 
routine surgical neuropathology & it’s crucial to 
differentiate them from metastatic tumours. 
Categorization is more problematic in such cases 
due to various parameters including presence of 
necrosis & small sample size due to stereotactic 
biopsies. From the present study it is concluded 
that IHC is a valuable technique & the best 
effective combination in diagnosing metastatic 
tumours of central nervous system are GFAP & 
CAM5.2. 
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